Cardea Services

Belkins
Cardea is a national organization with offices in Oakland, California; Austin, Texas; and Seattle, Washington. For more than 40 years, we have provided training, organizational development, and research and evaluation services to improve organizations’ abilities to deliver accessible, high quality, culturally proficient, and compassionate services to their clients.

Related News

PHARMA TECH

SAAMA LAUNCHES ACTIVE SAFETY ANALYTICS FOR PHARMA (ASAP), CO-BUILT WITH GILEAD TO TRANSFORM SAFETY SURVEILLANCE

Saama Technologies, Inc. | October 27, 2020

news image

Saama Technologies, Inc. (“Saama”), the AI clinical analytics platform company, announced today the launch of the new Active Safety Analytics for Pharma (ASAP) product. ASAP is the first validated pharmacovigilance solution to leverage the U.S. Food and Drug Administration’s (FDA) Sentinel Common Data Model and the TreeScan methodology for detecting safety signals. ASAP was co-built with Gilead Sciences, a research-based biopharmaceutical company that discovers, develops and co...

Read More

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

HIT Consultant | April 07, 2020

news image

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More

PFIZER LAYS OUT GENE THERAPY ASPIRATIONS

BioPharma Dive | January 28, 2020

news image

Pfizer aims to be the third big pharma with a significant presence in gene therapy. Its plans to initiate this year three Phase 3 trials targeting mutation-driven blood and muscular diseases would make it a large player in this cutting-edge area of medicine. The difference between Pfizer and its Swiss rivals Novartis and Roche is that its treatments for muscular dystrophy and hemophilia do not look like they will be the first to market. With hopes that gene therapy could be a one-and-done treatm...

Read More

PRACTICE MANAGEMENT

AZURITY PHARMACEUTICALS TO ACQUIRE AND MERGE WITH ARBOR PHARMACEUTICALS

Azurity Pharmaceuticals, Inc. | August 24, 2021

news image

Azurity Pharmaceuticals, Inc. and Arbor Pharmaceuticals, Inc. today announced they have entered into a definitive agreement in which Azurity will be acquiring Arbor from existing investors including JW Asset Management and KKR. Following the completion of the transaction, which is subject to regulatory approvals, Azurity and Arbor will merge, creating a leading company offering innovative, high-value products to meet the unique needs of patients with underserved conditions. Financial details of ...

Read More

PHARMA TECH

Saama Technologies, Inc. | October 27, 2020

news image

SAAMA LAUNCHES ACTIVE SAFETY ANALYTICS FOR PHARMA (ASAP), CO-BUILT WITH GILEAD TO TRANSFORM SAFETY SURVEILLANCE

Saama Technologies, Inc. (“Saama”), the AI clinical analytics platform company, announced today the launch of the new Active Safety Analytics for Pharma (ASAP) product. ASAP is the first validated pharmacovigilance solution to leverage the U.S. Food and Drug Administration’s (FDA) Sentinel Common Data Model and the TreeScan methodology for detecting safety signals. ASAP was co-built with Gilead Sciences, a research-based biopharmaceutical company that discovers, develops and co...

Read More

HIT Consultant | April 07, 2020

news image

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More

BioPharma Dive | January 28, 2020

news image

PFIZER LAYS OUT GENE THERAPY ASPIRATIONS

Pfizer aims to be the third big pharma with a significant presence in gene therapy. Its plans to initiate this year three Phase 3 trials targeting mutation-driven blood and muscular diseases would make it a large player in this cutting-edge area of medicine. The difference between Pfizer and its Swiss rivals Novartis and Roche is that its treatments for muscular dystrophy and hemophilia do not look like they will be the first to market. With hopes that gene therapy could be a one-and-done treatm...

Read More

PRACTICE MANAGEMENT

Azurity Pharmaceuticals, Inc. | August 24, 2021

news image

AZURITY PHARMACEUTICALS TO ACQUIRE AND MERGE WITH ARBOR PHARMACEUTICALS

Azurity Pharmaceuticals, Inc. and Arbor Pharmaceuticals, Inc. today announced they have entered into a definitive agreement in which Azurity will be acquiring Arbor from existing investors including JW Asset Management and KKR. Following the completion of the transaction, which is subject to regulatory approvals, Azurity and Arbor will merge, creating a leading company offering innovative, high-value products to meet the unique needs of patients with underserved conditions. Financial details of ...

Read More